- GSK goes to China for $1B siRNA deal in Arrowhead's obesity laneGSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. The UK pharma is teaming with Suz…Endpoints · 2mo ago↗ source
- <![CDATA[Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management]]><![CDATA[Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.]]>onclive · 2mo ago↗ source
- <![CDATA[Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration]]><![CDATA[New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.]]>